Table 2.

Developed serology tests for SARS-CoV-2 detection by different companies and researchers.

Developer	Platform	Target antigen	Target antibody	Other features	References
Abbott Laboratories	CMIA	Nucleocapsid	IgG	Return 100–200 test results in 1 h, specificity 99.6%, and sensitivity of 100%	Abbott Laboratories (2020b)
DiaSorin	CMIA	Spike	IgG	Fully automated, quantitative, 97.4% sensitivity, 98.5 specificity	DiaSorin (2020)
Pharmact AG	Lateral flow assay	–	IgG and IgM	POC, results in 20 min, can determine the phase of the disease, 99.8% agreement with PCR for non-affected cases	Pharmact (2020)
Hangzhou Biotest Biotech	Lateral flow assay	Spike	IgG and IgM	100% specificity for IgM and IgG, 100% sensitivity for IgM and 93.3% for IgG	(Hangzhou Biotest Biotech Company, 2020)
Cellex	Lateral flow assay	Spike and Nucleocapsid	IgG and IgM	93.8% sensitivity, 96% specificity, return results in 15–20 min	Cellex (2020)
ChemBio Diagnostic Systems	Lateral flow assay	Nucleocapsid	IgG and IgM	100% sensitivity for IgM and IgG after 15 days, 100% specificity for IgM and 95.9% for IgG, return results in 15 min	(ChemBio Diagnostic Systems, 2020)
Bio-Rad	ELISA	Nucleocapsid	Pan-Ig	92.2% sensitivity, 99.6% specificity	Bio-Rad (2020)
Mount Sinai	ELISA	receptor binding domain	IgG	Indirect detection of antibody, 92% sensitivity, 100% specificity	Mount Sinai (2020)
Euroimmun	ELISA	Spike	IgG	90% sensitivity, 100% specificity, deliver the result in 2 and a half h	Euroimmun (2020b)
Beijing Wantai Biological Pharmacy	ELISA	receptor binding domain	IgG, IgM, and IgA	6.7% sensitivity, 97.5% specificity	(Beijing, 2020)
CDC	ELISA	Spike	IgG and IgM	ELISA-based, specificity >99%, sensitivity of 96%	(Freeman et al., 2020)
The Beroni Group with Tianjin University	–	–	–	Applying nanobody-based technology, improved detection rate and accuracy, high stability, less immunogenic	(Tianjin University, 2020)